The CNTN/RCEN Executive Committee, was established to review and provide feedback to investigators on their proposed trials, and subsequently to facilitate the conduct of multi-center clinical trials in nephrology. This Committee is comprised of Canadian experts in randomized trial methodology and conduct. They can provide feedback to investigators at any stage of the trial proposal, offering suggestions on how to improve the methodology with the goal of increasing success of peer-reviewed funding. In addition, this Committee has developed a network of participating clinical trial sites that can be contacted by investigators for patient recruitment.
The committee thus offers three types of support to investigators:
- Brief review by one committee member with feedback
- Formal review by 2 reviewers and discussion with entire committee, with potential for Letter of Endorsement that can be sent to funding agencies
- Facilitation of sites for multi-centre trials
Rita Suri, Chair Dr. Suri's is an Associate Professor and Clinical Nephrologist at the Centre Hospitalier de l'Université Montréal (CHUM). She received formal training in observational methods and randomized trials at Western University. Her main research interests are in intensive hemodialysis therapies and dialysate composition. She has served as in internal reviewer for the Canadian Institutes of Health Research CIHR Randomized Controlled Trials Panel since 2007.
Michael Walsh, Vice-chair Dr. Michael Walsh is a specialist in Nephrology at St. Joseph's Healthcare and an Assistant Professor in the Departments of Medicine and Clinical Epidemiology & Biostatistics McMaster University. He has a Master's degree in Epidemiology from the University of Calgary, and a PhD in Health Research Methodology from McMaster University. In addition to his graduate work, he completed advanced fellowships in vasculitis at the University of Cambridge, UK, and the conduct of international studies at McMaster University. Dr. Walsh holds a New Investigator award from the Kidney Research Scientist Core Education and National Training Program (www.krescent.ca) for his research on the treatment of kidney diseases. He has special interests in the treatment of autoimmune kidney disease, and end-stage renal disease. In order to conduct large studies of these disease, Dr. Walsh is a member of several research organizations including the European Vasculitis Study Group (www.vasculitis.org), the Vasculitis Clinics Research Consortium (http://rarediseasesnetwork.epi.usf.edu/vcrc/index.htm), the Population Health Research Institute (www.phri.ca), the Canadian Network and Centre for Trials Internationally (www.cannectin.ca), and Clinical Advances through research and information translation (www.clarityresearch.ca).
Brendan Barrett, MB MSc FACP FRCPC, Dr. Brendan Barrett is a graduate of University College Cork, Ireland. He has been in Canada since 1987. Dr. Barrett is currently Divisional Chief of Nephrology at Eastern Health in Newfoundland and a Professor of Medicine at Memorial University of Newfoundland. Apart from clinical work, Dr. Barrett is involved in the undergraduate and postgraduate curricula. He also teaches in a graduate degree program for Clinical. Epidemiology. His current research interests in Nephrology include Care of Predialysis Patients, Experiences of Patient Life on Hemodialysis, Role of biomarkers in CKD, Clinical Trials in Hypertension and a range of health care delivery projects with emphasis on Evaluation of Programs from the point of view of efficiency and cost efficiency. Dr. Barrett currently chairs the Clinical Trials Scientific Committee of the CANN-NET network.
Catherine Clase, MB BChir MA MSc FRCPC FASN Catherine Clase completed degrees in pathology and in medicine at Christ’s College, Cambridge, UK, before moving to Canada for clinical training in internal medicine (Memorial University of Newfoundland), nephrology and health research methodology (McMaster University). Between 1997 and 2001 she was an assistant professor at Dalhousie University. She returned to McMaster University in 2001 as an associate professor in nephrology, and associate member of the department of clinical epidemiology and biostatistics. Research interests include the population epidemiology of chronic renal insufficiency and the prevention of thrombotic and bleeding complications in chronic renal insufficiency and dialysis. Conflict of interest disclosure (consultation, advisory board membership or research funding): Pfizer (dalteparin), Leo Pharma (tinzaparin), Astellas, Janssen, Amgen, Boehringer-Ingelheim
Francois Madore is a senior clinical scientist in epidemiology at Université de Montréal. He is the director of the research center at Hôpital du Sacré-Coeur de Montréal. Dr. Madore's research interests focus on the role of biomarkers and predictors of cardiovascular disease in patients with chronic kidney disease. Dr. Madore is a scholar of the Fonds de la recherche en santé du Québec (FRSQ). Research funding in recent years include operating grants from the Canadian Institutes of Health Research (CIHR) and the Kidney Foundation of Canada (KFOC).
Braden Manns, MD, MSc, FRCPC Dr. Manns is a specialist in Internal Medicine and Kidney Diseases at the University of Calgary. He has a Master's in Health Economics from the University of York, UK, and has been on faculty in the Departments of Medicine and Community Health Sciences since 2001. He is a Health Scholar from Alberta Innovates-Health Solutions, with research expertise in applied health economics, and knowledge translation. He is the past Chair of the Canadian Expert Drug Advisory Committee, a 13 member federal Committee that makes recommendations to provincial drug insurance plans as to whether to add new pharmaceuticals, and a past member of the Expert Drug Evaluation and Therapeutics Committee for Alberta Health. Through these positions, he has links with many Healthy Ministry staff across Canada. Dr. Manns also serves as a team co-Lead for the Interdisciplinary Chronic Disease Collaboration, and is the Chair of the Canadian Kidney Knowledge Translation and Generation Network, funded by CIHR and Kidney Foundation of Canada. He is the President elect for the Canadian Society of Nephrology
Susan Samuel, MD FRCPC MSc Dr. Susan M. Samuel is a clinician scientist and pediatric nephrologist at the Alberta Children's Hospital. She is an Assistant Professor in the Departments of Pediatrics and Community Health Sciences at the University of Calgary, Canada. She is supported by salary awards from both the Canadian Child Health Clinician Scientist Program (CCHCSP) and Kidney Research Scientist Core Education and National Training Program (KRESCENT). She has experience in successfully leading multi-centre collaborative health services research in paediatric nephrology using national administrative and organ failure registry datasets. Her research goals are to identify modifiable and/or preventable factors that cause death and disability in children with chronic kidney disease.
Nadia Zalunardo, MD Dr. Zalunardo received her MD degree and completed her postgraduate training in Internal Medicine and Nephrology at UBC. During her additional fellowship training she pursued research in the field of renovascular disease and completed a Master of Science degree in Epidemiology at the Harvard School of Public Health. She has been on staff at UBC since 2006 and is medical director of the CKD clinic at Vancouver General Hospital.
Claudio Rigatto, MD, FRCPC, MSc Dr. Rigatto is a trained clinical epidemiologist. His research is focused on biomarkers as predictors of outcomes in both acute and chronic kidney disease. He is a lead investigator with the Winnipeg Cardiac Surgery Cohort, a prospective cohort study of renal outcomes after heart surgery, where his research focuses on intraoperative biomarkers of AKI. He is also a member of the CANPREDDICT Consortium, a prospective cohort of 2500 CKD patients followed by nephrologists across Canada exploring utility of newer markers of renal and vascular health in prediction of patient-important outcomes in CKD.
Catherine Morgan, MD, FRCPC, MSc Dr. Catherine Morgan is a pediatric nephrologist at the Strollery Children's Hospital and an Assistant Professor in the Department of Pediatrics at the University of Alberta, Canada. She has a Master's degree in Clinical Epidemiology and Biostatistics from the University of Alberta. Her research is focused on cardiac surgery associated with acute kidney injury in children. She is a lead investigator of a multcentre, prospective cohort study evaluating long-term renal outcomes of children experiencing AKI during critical illness. Research funding includes operating grants from the Canadian Institutes of Health Research (CIHR) and the Women and Children's Health Research Institute (WCHRI).